848398-41-4

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DICHLORO-5,7-DIHYDROFURO[3,4-D]PYRIMIDINE is used as a reagent for the synthesis of substituted pyrimidinediamines. These compounds are potent dual BRD4-kinase inhibitors, which have shown promise in treating cancer. The application of this reagent in the development of these inhibitors is crucial for advancing cancer therapies and improving patient outcomes.

InChI:InChI=1/C6H4Cl2N2O/c7-5-3-1-11-2-4(3)9-6(8)10-5/h1-2H2

Upstream product

• 89898-51-1 ethyl tetrahydrofuran-3-one 4-carboxylate 
• 848398-40-3 5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 1542710-75-7 N-benzyl-2-(2-methyl-2H-indol-1(7aH)-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS

CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R' is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.